← Back to Search

Behavioural Intervention

CGM Group for Diabetes

N/A
Waitlist Available
Led By Athena Philis-Tsimikas, MD
Research Sponsored by Scripps Whittier Diabetes Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

"This trial will study how adding continuous glucose monitoring devices to a text messaging diabetes education program can help patients with type 2 diabetes who do not use insulin. They will monitor the patients for 6 months

Who is the study for?
This trial is for patients with type 2 diabetes who do not use insulin. It's designed to see if adding a continuous glucose monitoring (CGM) device to a text messaging education program can help manage their condition over six months.Check my eligibility
What is being tested?
The study tests whether the Dulce Digital Text Messaging Intervention, when combined with real-time CGM devices, improves diabetes management in non-insulin using type 2 diabetes patients compared to just the educational texts alone.See study design
What are the potential side effects?
Potential side effects may include skin irritation from the CGM device adhesive and possible anxiety or stress due to constant awareness of glucose levels. The text messaging intervention itself has no physical side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
HbA1c
Secondary outcome measures
CGM Metric Time Below Range
CGM Metric Time above Range
CGM Metric Time in Range
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Usual Care Blood Glucose Monitoring GroupExperimental Treatment1 Intervention
Participants will use standard blood glucose monitoring devices that are covered by health insurance.
Group II: CGM GroupExperimental Treatment2 Interventions
Participants will be provided continuous glucose monitors (Dexcom G7) to monitor blood glucose for the entire duration of this study (i.e., one new device every 10 days for a total of 18 devices to last up to 6 months).

Find a Location

Who is running the clinical trial?

Scripps Whittier Diabetes InstituteLead Sponsor
17 Previous Clinical Trials
5,249 Total Patients Enrolled
3 Trials studying Diabetes
1,422 Patients Enrolled for Diabetes
Athena Philis-Tsimikas, MDPrincipal InvestigatorScripps Health
13 Previous Clinical Trials
4,519 Total Patients Enrolled
3 Trials studying Diabetes
1,422 Patients Enrolled for Diabetes

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment for participants in this study currently ongoing?

"According to the details on clinicaltrials.gov, recruitment for this trial has ceased. The trial was first listed on 5/1/2024 and had its latest update on 2/28/2024. However, there are currently 1378 other active trials seeking participants."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Enhancing Digitally Delivered Diabetes Education With Real-Time CGM
2024. "Enhancing Digitally Delivered Diabetes Education With Real-Time CGM". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06296550.
~93 spots leftby Apr 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top